[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - ncbi.nlm.nih.gov
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
[PDF][PDF] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - pdfs.semanticscholar.org
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - pubmed.ncbi.nlm.nih.gov
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - europepmc.org
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - oncotarget.com
Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct
comparative analysis of icotinib, gefitinib, and erlotinib in a... | Oncotarget Online ISSN: 1949-2553 …
comparative analysis of icotinib, gefitinib, and erlotinib in a... | Oncotarget Online ISSN: 1949-2553 …
Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - oncotarget.com
Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct
comparative analysis of icotinib, gefitinib, and erlotinib in a... | Oncotarget Online ISSN: 1949-2553 …
comparative analysis of icotinib, gefitinib, and erlotinib in a... | Oncotarget Online ISSN: 1949-2553 …